Propanc Biopharma Gets Japanese Patent for Proenzymes Composition

Propanc Biopharma, Inc., a biopharmaceutical firm specializing in innovative treatments for recurring and metastatic cancer, has recently announced significant milestones in its intellectual property portfolio. The company received a Certificate of Grant for its "proenzymes composition" patent from the Japanese Patent Office. This patent includes claims regarding the dosing regimen for Propanc's leading product, PRP, which is moving into clinical development. It marks the fourth Japanese patent granted in this jurisdiction for the company. Additionally, a Certificate of Grant was also issued by the Intellectual Property Corporation of Malaysia for a cancer treatment involving therapeutic quantities of two proenzymes: trypsinogen and chymotrypsinogen. This is the third patent granted in Malaysia.

Currently, Propanc’s intellectual property portfolio comprises 93 patents filed in major global territories, focusing on the use of PRP against solid tumors. The proenzymes composition patent is a pivotal part of this portfolio as it defines potential future clinical dosage ranges for PRP, essential as the company progresses into early-stage clinical development. Japan is recognized as a crucial pharmaceutical market, with revenue projections hitting $46.36 billion in 2024. Oncology drugs dominate this sector, anticipated to reach $8.95 billion, fueled by the growing demand for innovative treatments due to an aging population and rising chronic disease prevalence.

The cancer treatment patent details a method aimed at targeting and eliminating cancer stem cells (CSCs) using PRP, thereby slowing cancer progression. Metastatic cancer, the spread of cancer from its primary site, remains the leading cause of death among cancer patients. Malaysia, a significant Southeast Asian nation, expects its pharmaceutical market revenue to reach $13.40 billion in 2024, with oncology drugs constituting the largest segment at $2.40 billion.

James Nathanielsz, Propanc’s Chief Executive Officer, emphasized the company’s strategy to build a robust and comprehensive intellectual property portfolio around the use of proenzymes as a novel treatment for advanced solid tumors. Propanc plans to expand its portfolio by filing additional provisional patent applications as PRP advances into clinical stages. Intellectual property protection is a cornerstone of their drug development strategy, crucial for safeguarding the value of their promising lead product candidate, PRP. Nathanielsz expressed optimism about advancing PRP into a Phase 1b clinical study in patients with advanced cancer, aiming to develop a novel therapy for treating and preventing metastatic cancer from solid tumors by targeting and eradicating CSCs without the side effects typically associated with standard treatments.

PRP is a combination of two proenzymes, trypsinogen and chymotrypsinogen, derived from the bovine pancreas and administered via intravenous injection. The synergistic ratio of 1:6 has been found to inhibit the growth of various tumor cells, including those from pancreatic, ovarian, kidney, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.

Propanc Biopharma, Inc. is dedicated to developing a novel approach to prevent the recurrence and metastasis of solid tumors using pancreatic proenzymes. These enzymes are believed to stimulate biological reactions that could act as the body’s primary defense against cancer. The company’s research focuses on pancreatic, ovarian, and colorectal cancers, aiming to provide patients with an innovative therapeutic option that targets and eradicates cancer stem cells.